CAR-T cell therapy in hematological malignancies: current opportunities and challenges
X Zhang, L Zhu, H Zhang, S Chen, Y Xiao - Frontiers in immunology, 2022 - frontiersin.org
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer
treatment, and it has achieved unprecedented success in hematological malignancies …
treatment, and it has achieved unprecedented success in hematological malignancies …
Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
A Dimitri, F Herbst, JA Fraietta - Molecular cancer, 2022 - Springer
Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …
cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition …
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
G Ghilardi, JA Fraietta, JN Gerson, VM Van Deerlin… - Nature Medicine, 2024 - nature.com
We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy
M Smith, A Dai, G Ghilardi, KV Amelsberg, SM Devlin… - Nature medicine, 2022 - nature.com
Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has led to unprecedented
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
responses in patients with high-risk hematologic malignancies. However, up to 60% of …
Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
[HTML][HTML] Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow …
Background Several commercial and academic autologous chimeric antigen receptor T-cell
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
(CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B …
Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia
G Ottaviano, C Georgiadis, SA Gkazi, F Syed… - Science translational …, 2022 - science.org
Genome editing of allogeneic T cells can provide “off-the-shelf” alternatives to autologous
chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain …
chimeric antigen receptor (CAR) T cell therapies. Disruption of T cell receptor α chain …
The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients
F Marofi, HS Rahman, ZMJ Al-Obaidi, AT Jalil… - Stem Cell Research & …, 2021 - Springer
Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …
hematological malignancy that affects the myeloid cell progenies and challenges patients of …